@article{5a16639e4113485b8b6363beaf0a0322,
title = "The best of times, the worst of times for psychiatric disease",
abstract = "As long-awaited advances in psychiatric genetics begin to materialize in force, promising to steer us safely to the best of times in psychiatric disease research, many pharmaceutical companies pull away from the challenge of drug development, threatening to bring us to the worst of times for the field. There is a real danger of missed opportunities and a sense of urgency for defining a clear path forward.",
author = "Maria Karayiorgou and Jonathan Flint and Gogos, {Joseph A.} and Malenka, {Robert C.} and Bargmann, {Cornelia I.} and Boyden, {Edward S.} and Bullmore, {Edward T.} and Chan, {Anthony W.} and Michael Davis and Karl Deisseroth and Dolmetch, {Ricardo E.} and Kevin Eggan and Fears, {Scott C.} and Freimer, {Nelson B.} and Geschwind, {Daniel H.} and Joshua Gordon and Nickerson, {Debbie A.} and Pierre Vanderhaeghen and Richard Axel and Zuker, {Charles S.} and Fischbach, {Gerald D.}",
note = "Funding Information: Support from the US National Institutes of Health (grant 5R13MH091947 to M.K.) and the Martinos family is gratefully acknowledged.",
year = "2012",
month = jun,
doi = "10.1038/nn.3115",
language = "English",
volume = "15",
pages = "811--812",
journal = "Nature Neuroscience",
issn = "1097-6256",
publisher = "Nature Research",
number = "6",
}